Dyadic International Inc (DYAI)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $13.10M
Last updated: Nov 17, 2026 at 10:46 AM ET
Dyadic International Inc (DYAI) Earnings: Report Dates and Results
Dyadic International (DYAI) is expected to report earnings on Mar 23, 2027. In the quarter ended Sep 30, 2026, Dyadic International reported EPS of -$0.05, below the -$0.03 estimate. It beat the EPS estimate in 1 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
DYAI has an expected report date of Mar 23, 2027.
DYAI Earnings Call
The latest DYAI earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 31 quarters below that had an estimate, DYAI beat 9, missed 17 and matched 5. Revenue for the quarter ended Sep 30, 2026 was $449101, down 61.3% from $1.16M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.05 | -$0.03 | -$0.06 - -$0.03 | -66.67% | Miss | N/A | 3 | 0 up, 0 down | Nov 12, 2026 | $449101 |
| Jun 30, 2026 | -$0.06 | -$0.03 | -$0.04 - -$0.03 | -100.00% | Miss | N/A | 3 | 0 up, 0 down | Aug 12, 2026 | $961138 |
| Mar 31, 2026 | -$0.05 | -$0.04 | -$0.05 - -$0.04 | -25.00% | Miss | N/A | 2 | 1 up, 0 down | May 13, 2026 | $1.11M |
| Dec 31, 2025 | -$0.04 | -$0.04 | N/A | -11.03% | Miss | N/A | 1 | 1 up, 0 down | Mar 25, 2026 | $235716 |
| Sep 30, 2025 | -$0.06 | -$0.04 | -$0.06 - -$0.03 | -50.00% | Miss | N/A | 3 | 0 up, 0 down | Nov 12, 2025 | $1.16M |
| Jun 30, 2025 | -$0.06 | -$0.06 | N/A | 0.00% | In line | N/A | N/A | 0 up, 0 down | Aug 13, 2025 | $463449 |
| Mar 31, 2025 | -$0.07 | N/A | N/A | N/A | N/A | N/A | N/A | 0 up, 0 down | May 14, 2025 | $183100 |
| Dec 31, 2024 | -$0.05 | -$0.04 | N/A | -25.00% | Miss | N/A | 1 | 0 up, 0 down | Mar 26, 2025 | $817376 |
| Sep 30, 2024 | -$0.01 | -$0.07 | -$0.07 - -$0.07 | +85.71% | Beat | N/A | 1 | 0 up, 0 down | Nov 12, 2024 | $1.96M |
| Jun 30, 2024 | -$0.07 | -$0.06 | -$0.07 - -$0.06 | -16.67% | Miss | N/A | 2 | 0 up, 0 down | Aug 13, 2024 | $385896 |
| Mar 31, 2024 | -$0.07 | -$0.07 | N/A | +0.43% | Beat | -332.3% | N/A | 0 up, 0 down | May 14, 2024 | $334617 |
| Dec 31, 2023 | -$0.08 | -$0.06 | -$0.08 - -$0.05 | -33.33% | Miss | N/A | 2 | 0 up, 0 down | Mar 28, 2024 | $686535 |
| Sep 30, 2023 | -$0.06 | -$0.06 | N/A | 0.00% | In line | N/A | 1 | 0 up, 0 down | Nov 8, 2023 | $397060 |
| Jun 30, 2023 | -$0.07 | -$0.05 | -$0.08 - -$0.02 | -40.00% | Miss | N/A | 2 | 0 up, 0 down | Aug 9, 2023 | $837159 |
| Mar 31, 2023 | $0.03 | -$0.03 | N/A | +200.00% | Beat | N/A | N/A | 0 up, 0 down | May 10, 2023 | $978052 |
| Dec 31, 2022 | -$0.07 | -$0.07 | -$0.10 - -$0.07 | 0.00% | In line | N/A | 2 | 0 up, 0 down | Mar 29, 2023 | $743726 |
| Sep 30, 2022 | -$0.06 | -$0.09 | -$0.11 - -$0.08 | +33.33% | Beat | N/A | 2 | 0 up, 0 down | Nov 10, 2022 | $879597 |
| Jun 30, 2022 | -$0.12 | -$0.07 | -$0.12 - -$0.05 | -71.43% | Miss | N/A | 3 | 0 up, 1 down | Aug 10, 2022 | $658553 |
| Mar 31, 2022 | -$0.09 | -$0.14 | N/A | +35.71% | Beat | N/A | 2 | 0 up, 0 down | May 12, 2022 | $648427 |
| Dec 31, 2021 | -$0.15 | -$0.02 | -$0.06 - $0.01 | -650.00% | Miss | N/A | 2 | 0 up, 0 down | Mar 29, 2022 | $313290 |
| Sep 30, 2021 | -$0.06 | -$0.10 | -$0.10 - -$0.09 | +40.00% | Beat | N/A | 2 | N/A | Nov 10, 2021 | $692929 |
| Jun 30, 2021 | -$0.14 | -$0.09 | -$0.09 - -$0.09 | -55.56% | Miss | N/A | 2 | N/A | Aug 12, 2021 | $937092 |
| Mar 31, 2021 | -$0.12 | $0.09 | $0.09 - $0.09 | -233.33% | Miss | N/A | 1 | N/A | May 13, 2021 | $460520 |
| Dec 31, 2020 | -$0.07 | -$0.08 | -$0.08 - -$0.08 | +12.50% | Beat | N/A | 2 | N/A | Mar 30, 2021 | $345917 |
| Sep 30, 2020 | -$0.09 | -$0.07 | -$0.09 - -$0.07 | -28.57% | Miss | N/A | 2 | N/A | Nov 12, 2020 | $416361 |
| Jun 30, 2020 | -$0.10 | -$0.07 | -$0.07 - -$0.02 | -42.86% | Miss | N/A | 2 | N/A | Aug 13, 2020 | $524271 |
| Mar 31, 2020 | -$0.08 | -$0.02 | -$0.02 - -$0.02 | -300.00% | Miss | N/A | 1 | N/A | May 14, 2020 | $315372 |
| Dec 31, 2019 | -$0.07 | -$0.07 | N/A | 0.00% | In line | N/A | N/A | N/A | Mar 30, 2020 | $433168 |
| Sep 30, 2019 | -$0.06 | -$0.07 | N/A | +14.29% | Beat | N/A | N/A | N/A | Nov 13, 2019 | $454507 |
| Jun 30, 2019 | -$0.10 | -$0.07 | N/A | -42.86% | Miss | N/A | N/A | N/A | Aug 13, 2019 | $390874 |
| Mar 31, 2019 | -$0.08 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 9, 2019 | $402527 |
| Dec 31, 2018 | -$0.02 | -$0.06 | N/A | +66.67% | Beat | N/A | N/A | N/A | Mar 27, 2019 | $686875 |
| Sep 30, 2018 | -$0.06 | -$0.06 | N/A | 0.00% | In line | N/A | N/A | N/A | Dec 18, 2018 | $262960 |
| Jun 30, 2018 | -$0.06 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 9, 2018 | $161286 |
| Mar 31, 2018 | -$0.07 | N/A | N/A | N/A | N/A | -200.0% | N/A | N/A | May 10, 2018 | $184330 |
| Dec 31, 2017 | -$0.02 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 27, 2018 | $157000 |
| Sep 30, 2017 | -$0.05 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 9, 2017 | $272491 |
| Jun 30, 2017 | -$0.05 | N/A | N/A | N/A | N/A | -440.1% | N/A | N/A | Aug 10, 2017 | $207402 |
| Mar 31, 2017 | $0.07 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 11, 2017 | $121527 |
| Dec 31, 2016 | -$0.06 | N/A | N/A | N/A | N/A | -103.7% | N/A | N/A | Mar 15, 2017 | $491050 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.23, after -$0.20 the year before. It was -$0.10 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.23 | N/A |
| Dec 31, 2024 | -$0.20 | N/A |
| Dec 31, 2023 | -$0.18 | N/A |
| Dec 31, 2022 | -$0.34 | N/A |
| Dec 31, 2021 | -$0.47 | N/A |
| Dec 31, 2020 | -$0.34 | N/A |
| Dec 31, 2019 | -$0.31 | N/A |
| Dec 31, 2018 | -$0.21 | N/A |
| Dec 31, 2017 | -$0.05 | N/A |
| Dec 31, 2016 | -$0.10 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,000 words across 7 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 5,977 | 7 | |
| 2026Q2 | Jun 30, 2026 | 4,449 | 6 | |
| 2026Q1 | Mar 31, 2026 | 4,737 | 9 | |
| 2025Q4 | Dec 31, 2025 | 6,191 | 8 | |
| 2025Q3 | Sep 30, 2025 | 6,056 | 8 | |
| 2025Q2 | Jun 30, 2025 | 4,776 | 10 | |
| 2025Q1 | Mar 31, 2025 | 4,304 | 7 | |
| 2024Q3 | Sep 30, 2024 | 5,483 | 6 |
2026Q3 Earnings Call
Opening remarks
Ping Rawson CFO Thank you. Good evening, and welcome, everyone, to Dyadic's Third Quarter 2026 Conference Call. I hope you have had the opportunity to review Dyadic's press release announcing financial results for the quarter ended September 30, 2026. You may access our release under the Investors section of the company's website at dyadic.com. Before we begin, I want to let you know that due to a Microsoft Outlook issue that has impacted many organizations, including Dyadic, we have not yet filed our quarterly report on Form 10-Q for the quarter ended September 30, 2026. We expect to file the Form 10-Q as soon as the system is back online and within the SEC filing deadline. The financial results we will discuss today are those in our press release, and they will be reflected in the Form 10-Q. On today's call, our President and Chief Operating Officer, Joe Hazelton, will review our Q3 2026 business and corporate highlights and provide commentary on the strategic direction of the company. Our CEO, Mark Emalfarb, will provide an update on our biopharmaceutical programs, and I will follow with a review of our financial results in more detail, after which we will hold a brief question-and-answer session. At this time, I would like to inform you that certain commentary made in this conference call may be considered forward-looking statements, which involve risks and uncertainties and other factors that could cause Dyadic's actual results, performance, scientific or otherwise, or achievements to be materially different from those expressed or implied by these forward-looking statements. Dyadic expressly disclaims any duty to provide updates to its forward-looking statements, whether because of new information, future events or otherwise. Participants are directed to the risk factors set forth in Dyadic's reports filed with the SEC. It is now my pleasure to pass the call to our President and COO, Joe Hazelton. Joe?
Joseph Hazelton President and COO Thanks, Ping, and thank you, everyone, for joining us today. Over the past several quarters, we've discussed Dyadic's transition from primarily developing protein production technologies toward building commercial businesses around our C1 and Dapibus platforms. During the third quarter, we continued making progress in that transition through initial direct product sales, broader distribution, additional partner-commercialized products, and advancing discussions with companies interested in our technologies and protein production portfolio. While these developments are encouraging, I want to put them in perspective. Our direct commercial sales remain modest, and customer qualification and adoption are taking longer than we originally anticipated. While we still have work ahead of us to establish meaningful and recurring product revenue, we are beginning to demonstrate that our protein production platforms can support commercial products through multiple business models, including direct sales, distribution, licensing, and partner-led commercialization.
Frequently Asked Questions About DYAI
When is Dyadic International's next earnings date?
Dyadic International's next earnings report is expected for Mar 23, 2027.
Did DYAI beat earnings estimates last quarter?
No. Dyadic International reported EPS of -$0.05 for the quarter ended Sep 30, 2026, below the -$0.03 estimate by 66.67%.
What EPS do analysts expect from DYAI next quarter?
The consensus EPS estimate for Dyadic International for the quarter ending Dec 31, 2026 is $0.01 from 5 analysts, with estimates from -$0.02 to $0.04.
How often does DYAI beat earnings estimates?
Dyadic International beat the EPS estimate in 1 of the 8 most recent quarters that had an estimate, with an average surprise of -24.00%.
DYAI pages: Overview, Earnings, Forecast, Financials, Competitors